LILeeberk Raja Inbaraj

Leeberk Raja Inbaraj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leeberk Raja Inbaraj has a total of 209 co-authors. Here are the top co-authors by number of shared publications:

  • Adhin Bhaskar

    Department of Statistics, ICMR - National Institute for Research in Tuberculosis, Chennai, India

    10 shared publications
  • Vignes Anand Srinivasalu

    Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India

    9 shared publications
  • Carolin Elizabeth George

    Bangalore Baptist Hospital

    8 shared publications
  • Jefferson Daniel

    Department of Pulmonary Medicine, Christian Medical College, Vellore, India

    7 shared publications
  • Mukesh Kumar Sathya Narayanan

    Department of Epidemiology, ICMR-National Institute for Research in Tuberculosis, Chennai, India

    7 shared publications
  • Gift Norman

    Department of Family Medicine and Community Health, Division of Community Health, Bangalore Baptist Hospital, Bengaluru, Karnataka, India

    6 shared publications

Latest Publications

  • Open Access

    Diagnostic test accuracy of the TriAGe+ score for detecting stroke in adults presenting with vertigo or dizziness: a protocol for systematic review and meta-analysis

    by Suvarna Jyothi Kantipudi, Suchanda Sahu, Radha K, Vijayakumar Balakrishnan, Ankita Tandon, Gunaseelan Rajendran, Adhin Bhaskar, Mukesh Kumar Sathya Narayanan, Leeberk Raja Inbaraj, Vignes Anand Srinivasalu, et al.

  • Open Access

    Diagnostic accuracy of high-risk HPV DNA and cytology in diagnosing precancerous and early malignant cervical lesions: a protocol for a systematic review and meta-analysis

    by Shrish Vijayakumar Raut, Mallika Sengupta, Pradeep S Anand, Balasubramanian Ganesh, Joshua Chadwick, Ramanandvignesh Pandiyan, Kavitha P. Kamath, Vignes Anand Srinivasalu, Adhin Bhaskar, Jefferson Daniel J, et al.

  • Open Access

    Clinical assessment and biomarkers for the detection of bacterial community-acquired pneumonia in children and adults: a protocol for systematic review of diagnostic accuracy

    by Jefferson Daniel, Mukesh Kumar Sathya Narayanan, Vignes Anand Srinivasalu, Adhin Bhaskar, Sharon Suresh, Bella Devaleenal Daniel, Balaji Ramraj, Dina Nair, Ranjit Immanuel James, Sudharsan Vasudevan, et al.

    Community-acquired pneumonia (CAP) is defined as an infection of the pulmonary parenchyma acquired in the community and outside the hospital setting. CAP i


  • A profile on the Truenat assays for the detection of pulmonary tuberculosis and rifampicin resistance

    by Leeberk Raja Inbaraj, Mukesh Kumar Sathya Narayanan, Priya Rajendran, Bella Devaleenal Daniel, Sivakumar Shanmugam, Banurekha Velayutham

    Early diagnosis and treatment initiation are essential to prevent ongoing tuberculosis (TB) transmission and reduce the disease burden. Smear microscopy, which is widely used test for diagnosis has limited sensitivity and does not detect rifampicin resistance. Truenat is a portable, battery-operated, chip-based test that can be placed in peripheral laboratories, serving as a point-of-care test. It also detects rifampicin resistance, which is crucial in the management of TB. Our review comprehensively covers the functionality and workflow of the Truenat MTB assay, in addition to its cost-effectiveness and diagnostic accuracy, based on recent evidence. We also discuss the merits and drawbacks of alternative diagnostic tests available for detecting TB and rifampicin resistance. Truenat assays are rapid molecular tests that revolutionized TB diagnosis, moving toward peripheral testing. Evidence indicates that the Truenat MTB Plus performs better than the original Truenat MTB, with an approximate LOD of 30 CFU/ml. The 2025 WHO guidelines rely exclusively on data from Truenat MTB Plus. We need larger studies on the newer Truenat MTB Ultima to evaluate its performance on tongue swabs. Additionally, data on the accuracy of Truenat MTB in children remains scarce, emphasizing the importance of further research in this group. Evidence regarding its accuracy in detecting rifampicin resistance is also limited, requiring larger studies and technological advancements. Truenat MTB will remain crucial in the fight to eliminate TB in the future.

  • Open Access

    Diagnostic accuracy of low-complexity, manual nucleic acid amplification tests for the detection of pulmonary and extrapulmonary tuberculosis in adults and adolescents: a systematic review and meta-analysis∗

    by Leeberk Raja Inbaraj, Vignes Anand Srinivasalu, Mukesh Kumar Sathya Narayanan, Adhin Bhaskar, Jefferson Daniel, Katie Scandrett, Alexei Korobitsyn, Nazir Ismail, Yemisi Takwoingi


  • Open Access

    Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis

    by Bhavani Perumal Kannabiran, Jayanthi Arthanari, Adhin Bhaskar, Mukesh Kumar Sathya Narayanan, Leeberk Raja Inbaraj

    Background & objectives: Evidence suggests that higher doses of rifampicin aid in faster culture conversion, but its effects on unfavourable outcomes are unclear. We aimed to synthesise evidence on the efficacy and safety of high-dose rifampicin (>15 mg/kg) containing anti-tuberculosis regimen compared to a regimen with standard dose of rifampicin in adults with pulmonary tuberculosis. Methods: We searched for studies from MEDLINE, Embase, Web of Science, Google Scholar, and the Cochrane Library without geographical restriction. We included randomised controlled trials that evaluated high-dose rifampicin (>15 mg/kg for 8 wk) with a six-month duration. Our outcomes of interest were sputum conversion at eight wk, mortality, treatment failure at six months, Grade 3 and Grade 4 hepatotoxicity, and adverse events leading to treatment discontinuation. Two authors independently screened titles, abstracts, and full texts and extracted data. We performed a meta-analysis using the RevMan web software as per the Cochrane Handbook for Systematic Reviews of Interventions. Results: Out of 3950 articles screened, we included nine for meta-analysis. High-dose rifampicin (≥15 mg/kg) showed little benefit compared to the standard dose for sputum conversion at eight wk [(83% vs. 78%, Relative risk (RR) 1.05 (95% confidence interval (CI): 1.0-1.09), Number needed to treat (NNT)-24)] and this benefit was higher as the rifampicin dose increased [20-30 mg RR: 1.07 (95% CI 1.02-1.14), NNT-17]; >30 mg RR: 1.12 (95% CI 1.04 -1.20) NNT-9]. However, treatment failure and mortality showed no benefit with high-dose rifampicin. Grade 3 and 4 hepatotoxicity and treatment discontinuation due to toxicity had a dose-response relationship and were significantly higher in the more than 30 mg/kg group [RR: 4.01 (95%CI 1.75-9.19), Number needed to harm -20]. Interpretation & conclusions: High doses of rifampicin (≥15 mg/kg) increased the rate of sputum culture conversion after two months of the intensive phase. There was no difference in mortality and treatment failure between high-dose rifampicin and standard arms. In the subgroup analysis, the 20-30 mg/kg dose exhibited a beneficial effect in sputum conversion with no significant risk of hepatotoxicity and adverse drug reactions (ADR) leading to treatment discontinuation. This dose could be administered with close monitoring of adverse events and hepatotoxicity. There is an urgent need for adequately powered trials that assess long-term treatment outcomes, including recurrence.


  • Open Access

    Low-complexity manual nucleic acid amplification tests for pulmonary tuberculosis in children

    by Leeberk Raja Inbaraj, Mukesh Kumar Sathya Narayanan, Jefferson Daniel, Vignes Anand Srinivasalu, Adhin Bhaskar, Bella Devaleenal Daniel, Tephilla Epsibha, Katie Scandrett, Priya Rajendran, Winsley Rose, et al.

    Background Accurate and prompt diagnosis of tuberculosis in children is challenging due to non‐specific clinical presentation and the low bacillary load of samples. Low‐complexity manual nucleic acid amplification tests (LC‐mNAATs) such as loop‐mediated isothermal amplification (TB‐LAMP) are World Health Organization (WHO)‐recommended rapid molecular diagnostic tests. Even in resource‐limited settings, they have good diagnostic accuracy in adults. Objectives To determine the diagnostic accuracy of LC‐mNAATs for the detection of pulmonary tuberculosis in children (< 10 years) with presumptive pulmonary tuberculosis. Secondary objectives 1. To compare the diagnostic accuracy of LC‐mNAATs and Xpert MTB/RIF Ultra for the detection of pulmonary tuberculosis in children with presumptive pulmonary tuberculosis. 2. To compare the diagnostic accuracy of LC‐mNAATs and smear microscopy for detecting pulmonary tuberculosis in children when TB‐LAMP is considered as a replacement test for smear microscopy. 3. To determine the diagnostic accuracy of LC‐mNAATs for the detection of pulmonary tuberculosis if used as an add‐on test amongst sputum smear‐negative children. 4. To investigate potential sources of heterogeneity in the diagnostic accuracy of LC‐mNAATs due to factors such as smear status, age, HIV status, setting, and tuberculosis burden. Search methods We searched CENTRAL, MEDLINE, Embase, Science Citation Index, Biosis Previews, Global Index Medicus, SCOPUS, WHO ICTRP, and ClinicalTrials.gov on 2 October 2023 for published articles and trials in progress without language or time limits. We screened the reference lists of included articles, conference abstracts, tuberculosis reviews, and guidelines. We searched ProQuest Dissertations & Theses A&I for dissertations. We approached the Stop TB Partnership, FIND, and other experts on tuberculosis for ongoing and unpublished studies. A WHO public call was made between 30 November 2023 and 15 February 2024 for ongoing and unpublished studies from manufacturers and researchers. Selection criteria We included cross‐sectional and cohort studies that evaluated LC‐mNAATs in children (< 10 years) against microbiological or composite reference standards. Our index test was TB‐LAMP, and comparator index tests were Xpert MTB/RIF Ultra and smear microscopy. The microbiological reference standard included automated liquid culture, solid culture, or a combination of both methods. We considered only design‐locked, marketed technologies. Data collection and analysis Four review authors, in pairs, independently screened titles and abstracts and assessed the full texts of potentially eligible articles. A fifth review author resolved any disagreements. We tailored and applied the QUADAS‐2 and QUADAS‐C tools to assess the risk of bias and applicability. Six review authors, in three pairs, extracted data and performed methodological quality assessment. A seventh review author resolved any disagreements. We contacted the primary study authors for missing data. We assessed the certainty of evidence using the GRADEpro GDT online tool. Main results We included four eligible studies (303 participants). Three studies took place in low‐ and middle‐income countries, with two studies from countries with a high tuberculosis burden. All four studies assessed different respiratory and non‐respiratory specimen types and evaluated TB‐LAMP against the microbiological reference standard. We judged one study to have an unclear risk of bias in two domains of QUADAS‐2. The risk of bias was low for most of the studies. One study recruited inpatients from tertiary hospitals, causing high applicability concerns. Three studies (67 children, including eight with pulmonary tuberculosis) evaluated respiratory samples (sputum, broncho‐alveolar lavage, and tracheal aspirate). The sensitivities were between 60% and 100%, and the specificities were between 95% and 100% (very low‐certainty (sensitivity) and low‐certainty (specificity) evidence). Three studies (176 participants, including 14 children with pulmonary tuberculosis) used gastric aspirate; the sensitivity was not estimable in two studies, and was 64% in the third study. The specificities were between 93% and 100%. The sensitivity was 100% (95% confidence interval (CI) 29 to 100), and the specificity was 96% (95% CI 88 to 100) in gastric lavage from one study. One study (144 participants, 12 children with pulmonary tuberculosis) assessed diagnostic accuracy using nasopharyngeal aspirate. The sensitivity was 58% (95% CI 28 to 85), and the specificity was 94% (95% CI 88 to 97). The same study (seven children with pulmonary tuberculosis) also evaluated stool specimens, and the sensitivity and specificity were 100% (95% CI 59 to 100) and 92% (95% CI 86 to 96), respectively. We did not perform a meta‐analysis due to limited data. Interpretation of the results Respiratory samples For every 1000 children tested, if 100 had tuberculosis according to culture, 60 to 100 with tuberculosis would be identified as positive by the TB‐LAMP. Of the 900 children without tuberculosis, 855 to 900 would be identified as negative by the test. Gastric aspirate For every 1000 children tested, if 100 had tuberculosis according to culture, 64 with tuberculosis would be identified as positive by the TB‐LAMP. Of the 900 children without tuberculosis, 837 to 900 would be identified as negative by the test. Gastric lavage For every 1000 children tested, if 100 had tuberculosis according to culture, 135 would be TB‐LAMP positive, of which 100 would have tuberculosis (true positives), and 35 would not have tuberculosis (false positives); 865 would be TB‐LAMP negative, of which 864 would not have tuberculosis (true negatives), and one would have tuberculosis (false negatives). Nasopharyngeal aspirate For every 1000 children tested, if 100 had tuberculosis according to culture, 112 would be TB‐LAMP positives, of which 58 would have tuberculosis (true positives), and 54 would not have tuberculosis (false positives); 888 would test negative, of which 846 would not have tuberculosis (true negatives), and 42 would have tuberculosis (false negatives). Stool For every 1000 children tested, if 100 had tuberculosis according to culture, 171 would be TB‐LAMP positive, of which 99 would have tuberculosis (true positives), and 72 would not have tuberculosis (false positives); 829 would test negative, of which 828 would not have tuberculosis (true negatives) and one child would have tuberculosis (false negative). Authors' conclusions Evidence on the diagnostic accuracy of LC‐mNAATs for the detection of pulmonary tuberculosis in children is limited due to few and small studies. Adequately powered studies evaluating LC‐mNAATs in children are needed.


  • Open Access

    Large Tuberculous Mass Lesions Involving the Brain: Outcomes and Management

    by Prasannakumar Palanikumar, Priyanka Gautam, Harshad Arvind Vanjare, Nagaraj Veerasamy, Mithun Mohan George, Leeberk Raja Inbaraj, Edmond Jonathan Gandham, Ajith Sivadasan, Rajiv Karthik, Abi Manesh

    : The optimal management of large tuberculous mass lesions (LTML) involving the central nervous system remains unclear. We conducted a single-center, retrospective, observational study that assessed the outcomes of patients with LTML from January 2010 to February 2023. An LTML was defined as a tuberculoma or tubercular abscess exceeding or equal to 3 cm. The primary outcome was independence in activities of daily living, as assessed by the modified Rankin Scale (mRS) at a follow-up of 6 months. Forty-six patients were identified during the study period. Their mean age was 27.6 ± 12 years, the median duration of antituberculous therapy (ATT) was 18 months, and the median duration of follow-up was 20 months (interquartile range 15.7–40). The favorable outcomes were 76.9% (10/13) for ATT alone, 62.5% (10/16) for ATT with steroids, 87.5% (7/8) for ATT with surgery, and 66.9% (6/9) for ATT, steroids, and surgery. The median mRS at baseline in the study was 2 (1–3), and at the 6 month follow-up, it was 1 (0–2). Adding steroids or surgical intervention to ATT did not significantly improve primary outcomes (P = 0.637). Further large-scale studies are necessary to confirm these preliminary observations.


  • Open Access

    Truenat MTB assays for pulmonary tuberculosis and rifampicin resistance in adults and adolescents

    by Leeberk Raja Inbaraj, Jefferson Daniel, Mukesh Kumar Sathya Narayanan, Vignes Anand Srinivasalu, Adhin Bhaskar, Katie Scandrett, Priya Rajendran, Richard Kirubakaran, Hemant D Shewade, Muniyandi Malaisamy, et al.

    Background Accurate and rapid diagnosis is crucial for ending the tuberculosis epidemic. Truenat assays are World Health Organization (WHO)‐recommended rapid molecular diagnostic tests that detect Mycobacterium tuberculosis complex and rifampicin resistance. Objectives Primary objective To assess the diagnostic accuracy of Truenat assays (MTB, MTB Plus, and MTB‐RIF Dx) for detecting pulmonary tuberculosis and rifampicin resistance in adults and adolescents with presumptive pulmonary tuberculosis. Secondary objectives To compare the diagnostic accuracy of Truenat assays and Xpert MTB/RIF Ultra for detecting pulmonary tuberculosis and rifampicin resistance and to investigate potential sources of heterogeneity (e.g. HIV status and smear status). Search methods We searched MEDLINE, Embase, Science Citation Index and Biosis previews, Global Index Medicus, SCOPUS, WHO ICTRP, and ClinicalTrials.gov for published articles and trials in progress on 16and 17 October 2023. We searched ProQuest Dissertations & Theses A&I for dissertations. We contacted tuberculosis experts for ongoing and unpublished studies. A WHO public call for data was made between 30 November 2023 and 15 February 2024. Selection criteria We included cross‐sectional and cohort studies that evaluated Truenat assays in sputum samples from adolescents and adults (aged 10 years and older). The microbiological reference standard for identifying pulmonary tuberculosis is culture. The reference standard for rifampicin resistance is a culture‐based drug susceptibility test. Two review authors independently screened titles and abstracts, and assessed the full texts of potentially eligible articles. A third review author resolved any disagreements. Data collection and analysis We tailored and applied the QUADAS‐2 and QUADAS‐C tools to assess the risk of bias and applicability. Two review authors independently extracted data for each included study, and a third review author resolved any disagreements. We performed meta‐analyses to estimate summary sensitivities and specificities using a bivariate model. We assessed the certainty of evidence using the GRADEpro GDT tool. Main results Of nine eligible articles, one contributed two distinct participant cohorts, which we considered as separate studies. Thus, we included 10 studies; three assessed Xpert Ultra. Most studies were set in low‐ and middle‐income countries with a high tuberculosis burden. Six studies (4081 participants, 1379 with tuberculosis) assessed Truenat MTB, and four studies (3073 participants, 750 with tuberculosis) assessed Truenat MTB Plus. Two studies (966 participants, 111 with rifampicin resistance) assessed Truenat MTB‐RIF Dx. Overall, the risk of bias in the included studies was low. Three of the 10 studies were judged to have high applicability concern in the patient selection domain. Detection of pulmonary tuberculosis The summary sensitivity of Truenat MTB was 87.6% (95% confidence interval (CI) 81.6 to 91.8; high‐certainty evidence), and the summary specificity was 86.1% (95% CI 70.1 to 94.3; moderate‐certainty evidence). For Truenat MTB Plus, the summary sensitivity was 90.6% (95% CI 83.7 to 94.8; high‐certainty evidence), and the summary specificity was 95.7% (95% CI 94.7 to 96.5; high‐certainty evidence). Based on the three comparative studies, the summary sensitivity of Truenat MTB was lower (81.0%, 95% CI 72.8 to 87.2) than that of Xpert Ultra (93.7%, 95% CI 90.4 to 95.9), while the summary specificity of Truenat MTB (97.0%, 95% CI 91.9 to 98.9) was marginally higher than Xpert Ultra (95.3%, 95% CI 90.9 to 97.7). Detection of rifampicin resistance The sensitivities from the two studies were 53% and 85% (moderate‐certainty evidence) and specificities were both 97% (high‐certainty evidence). Authors' conclusions Truenat MTB Plus had higher sensitivity and specificity than Truenat MTB. The high false‐positive rate for Truenat MTB is a concern. The sensitivity of Xpert Ultra was significantly higher than that of Truenat MTB, while specificity was slightly lower. Evidence on the accuracy of Truenat MTB‐RIF Dx was limited.


  • Open Access

    Diagnostic accuracy of screening and diagnostic tests used in a state-wide tuberculosis prevalence survey in India

    by Prathiksha Giridharan, Leeberk Raja Inbaraj, Asha Frederick, Sriram Selvaraju, Balaji Ramraj, Kannan Thiruvengadam, Bella Davaleenal Daniel, Chandrasekaran Padmapriyadarsini

    Prevalence surveys and active case findings for tuberculosis (TB) typically use symptoms and Chest X-ray for screening and a diagnostic test for microbiological confirmation. We report the performance of screening and diagnostic tests from a state-wide prevalence survey in India. We screened 130,932 individuals using chest X-ray (CXR) and symptom checklist. Sputum samples were obtained from eligible participants and subjected to Xpert/MTB RIF, smear microscopy, and culture. Cough over two weeks had higher sensitivity (41.6%, 95% CI: 31.6–52.1) and lower specificity (72.8%, 95% CI: 72.1–73.5) among all the symptoms. The sensitivity and specificity of abnormal CXR were 86.4% (95% CI:77.9–92.5) and 42.12% (95% CI, 41.3–42.8), respectively. Xpert/MTB RIF in the reference laboratory had the highest sensitivity (96.55% 95% CI: 88.0-99.5), and smear microscopy had the highest specificity (99.7% 95% CI: 99.6–99.8). The combined sensitivity and specificity of Xpert MTB/RIF along symptom screening and CXR were 97.9% (95% CI:92.6–99.7) and 4.9% (95% CI:4.67–5.33), respectively. The mobile van Xpert MTB/RIF was found to be highly specific (99.3%). We recommend a diagnostic algorithm consisting of symptom screening and CXR followed by WHO-recommended rapid molecular assays (mWRD) for future prevalence surveys and active case finding.